The induction of GSH synthesis by nanomolar concentrations of NO in endothelial cells: a role for γ-glutamylcysteine synthetase and γ-glutamyl transpeptidase  by Moellering, Douglas et al.
The induction of GSH synthesis by nanomolar concentrations of NO in
endothelial cells : a role for Q-glutamylcysteine synthetase and Q-glutamyl
transpeptidase
Douglas Moelleringa, Joanne Mc Andrewa, Rakesh P. Patela, Henry Jay Formanc,
R. Timothy Mulcahyd, Hanjoong Joa;b, Victor M. Darley-Usmara;b;*
aDepartment of Pathology, Molecular and Cellular Division, University of Alabama at Birmingham, Volker Hall Room GO38,
1670 University Boulevard, Birmingham, AL 35294-0019, USA
bCenter for Free Radical Biology, University of Alabama at Birmingham, Volker Hall Room GO38, 1670 University Boulevard,
Birmingham, AL 35294-0019, USA
cUniversity of Southern California, 1985, Zonal Ave., Los Angeles, CA 90033, USA
dDepartment of Human Oncology, University of Wisconsin-Madison, K4/316 CSC, 600 Highland Ave., Madison, WI 53792, USA
Received 18 February 1999; received in revised form 4 March 1999
Abstract Nitric oxide protects cells from oxidative stress
through a number of direct scavenging reactions with free
radicals but the effects of nitric oxide on the regulation of
antioxidant enzymes are only now emerging. Using bovine aortic
endothelial cells as a model, we show that nitric oxide, at
physiological rates of production (1^3 nM/s), is capable of
inducing the synthesis of glutathione through a mechanism
involving Q-glutamylcysteine synthetase and Q-glutamyl trans-
peptidase. This novel nitric oxide signalling pathway is cGMP-
independent and we hypothesize that it makes an important
contribution to the anti-atherosclerotic and antioxidant proper-
ties of nitric oxide.
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1. Introduction
Nitric oxide (NO) has been shown in a number of studies to
protect cells from the cytotoxicity of oxidants [1^3]. This may
be particularly important in chronic diseases of the vascula-
ture in which oxidants, or their metabolic by-products, are
thought to contribute to the pathophysiology of the disease
[4^8]. An important example of this is atherosclerosis, initi-
ated by hypercholesterolemia, which is associated with an
early loss of responses to endothelial-derived NO [4,8^11].
NO has been shown to protect the cells of the vasculature
by inhibiting the cell-dependent oxidation of low density lip-
oprotein (LDL) [3,12^14]. However, oxidized LDL (oxLDL)
has been shown to inhibit the NO production from the endo-
thelium as is known to occur in human atherosclerosis [15,16].
The intracellular antioxidant glutathione (GSH) protects
cells against oxidative stress and its synthesis and related me-
tabolism are now understood in some detail [17,18]. It is less
clear how exposure to reactive nitrogen species a¡ects GSH
metabolism. In the vasculature, GSH protects against oxLDL
by detoxifying the lipid intermediates formed during oxidation
and also protects against the loss of NO production from the
endothelium. Thus, there appears to be a mechanistic link
between intracellular levels of GSH, the loss of NO formation
in hypercholesterolemia and modi¢ed lipoproteins [19]. Since
oxLDL is likely to be formed in atherosclerotic vessels,
through multiple mechanisms, it is reasonable to postulate
that maintenance of essential antioxidants, such as GSH, is
important to retard atherosclerosis [6,15].
Under some circumstances, NO, or its metabolites, can re-
act with oxidants produced at sites of in£ammation such as
superoxide or hypochlorite. It may then exert e¡ects on the
cell that have been associated with cytotoxicity as in the case
of peroxynitrite [8]. These e¡ects can also occur with the very
high concentrations of NO formed on activation of the indu-
cible or type 1 NO synthase (NOS). Little is known, however,
of the e¡ects of NO on GSH metabolism at the concentra-
tions of NO formed in the normal vasculature.
In a recent study [20], we have shown that rates of produc-
tion of NO in the order of 8^12 nM/s induce GSH synthesis in
vascular smooth muscle cells (VSMCs) through the increased
activity and expression of the rate limiting enzyme for its
synthesis Q-glutamylcysteine synthetase (GCS). These rates
of NO formation are at the upper limit of the eNOS activity
and are probably not encountered under physiological condi-
tions in the vasculature but could be readily achieved if iNOS
is induced [8,21,22]. In vivo, the vasculature is responsive to
10^50 nM NO and under physiological conditions, this NO
production is stimulated by the £ow of blood over the endo-
thelium. The rate of NO production in the vasculature due to
blood £ow has been measured directly and found to be in the
order of 1^3 nM/s [23]. These rates of NO formation elicited
little or no e¡ect on the GSH levels in smooth muscle cells,
therefore we decided to test their e¡ect on endothelial cells
[20].
The rate-limiting enzyme in the GSH synthesis, GCS, con-
sists of two subunits, the catalytic (heavy) subunit and the
regulatory (light) subunit. The promoter regions for the heavy
and light subunits contain a number of transcription factor
binding sites including AP-1, Sp-1, NFU-B, ARE and EpRE
sites, all of which are potential targets for NO-dependent reg-
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ulation [24^26]. Recent data indicate that exogenous NO in-
creases the production of GSH in vascular VSMCs by increas-
ing the levels of mRNA for both the heavy and light subunit
of GCS [20].
In this study, we have investigated the potential of NO to
regulate the synthesis of the antioxidant GSH in bovine aortic
endothelial cells (BAECs) by treatment of the cells with
chemically diverse NO donors. We ¢nd that NO in the low
nM concentration range induces GSH synthesis in endothelial
cells through a process that is not dependent on the cGMP
signalling pathway but does require the activity of GCS and Q-
glutamyl transpeptidase (Q-GT). We hypothesize that this NO-
dependent induction of GSH synthesis contributes to its anti-
atherogenic e¡ects.
2. Materials and methods
2.1. Cell culture
BAECs harvested from descending thoracic aortas were maintained
(37‡C, 5% CO2) in a growth medium (DMEM (1 g/l glucose, Gibco)
containing 20% fetal calf serum (Atlanta Biologicals) without antibi-
otics [27]. Cells used in this study were between passages 5^13.
2.2. Measurement of the rate of decomposition of NO donors
S-nitrosopenicillamine (SNAP) or DetaNONOate (Alexis Biochem-
icals, San Diego, CA, USA) was added to cells in culture. The rate of
NO release from DetaNONOate was calculated from the published
half life of 20 h [28]. To measure the rate of NO release from SNAP,
the NO-dependent oxidation of oxymyoglobin was measured. Oxy-
myoglobin (30 WM) was added along with SNAP to cells and the
oxidation was followed by measuring the absorbance decrease at
580 nm over a period of 15 min incubation with cells. Concentration
changes were calculated using the O580nm = 14.4/mM/cm. Decomposed
SNAP was prepared by incubating the stock concentration of SNAP
(10 mM) under light for 48 h at 22‡C after which time no absorbance
at 340 nm could be detected indicating the complete decomposition of
the compound.
2.3. GSH and GCS activity measurements
Total GSH (tGSH) (GSH+GSSG) was measured using a spectro-
photometric assay coupling the thionitrobenzoate formation from di-
thionitrobenzoate with the GSH reductase activity [29]. The rates were
converted to tGSH concentrations using a standard curve generated
with authentic GSH. For determination of the GCS activity, cultured
cells were grown to con£uency in six well plates and after experimen-
tal manipulation, the medium was removed and the cells were washed
twice with ice-cold PBS. The cells were then scraped from the plates
into a 100 Wl volume of 100 mM Tris-Cl (pH 8.2), 50 mM KCl, 20 mM
MgCl2, 2 mM EDTA, 0.1% Triton X-100, centrifuged (4‡C, 20 min,
15 000Ug) and the supernatants removed. A 300 Wl aliquot of the
supernatant was then added to 700 Wl of a bu¡er containing
100 mM Tris (pH 8.2), 50 mM KCl, 20 mM MgCl2, 2 mM EDTA,
10 mM ATP, 5 mM glutamic acid and 5 mM K-aminobutyric acid.
The solution was incubated at 37‡C for 2 h before the reaction was
terminated by the addition of 200 Wl of 1 M perchloric acid. The
activity of GCS was then determined by measuring the formation of
Q-glutamyl-K-aminobutyric acid using HPLC analysis [30].
3. Results and discussion
3.1. NO induces GSH synthesis in endothelial cells
To determine whether NO induces GSH synthesis, BAECs
were exposed to two chemically distinct NO donors, SNAP
and DetaNONOate. Exposure of cells to SNAP for 12 h in-
creased the tGSH in a concentration-dependent manner (Fig.
1A). Concentrations as low as 50 WM SNAP signi¢cantly in-
creased the tGSH while 200 WM SNAP resulted in a maximal
e¡ect on tGSH levels (Fig. 1A). When the products of decom-
posed SNAP were used to treat BAECs, there was no increase
in the tGSH indicating that NO, or NO-derived species, were
responsible for these e¡ects rather than the decomposition
products of the NO donor. In a second series of experiments,
the time course for induction of tGSH by SNAP was deter-
mined. The basal level of total tGSH in the cells for these
experiments was approximately 30% higher than those used
in the experiment shown in Fig. 1A. These di¡erences in
tGSH levels have been observed by other laboratories and
are due to routine changes in the media and a consequent
variation in growth rates in the cell cultures [18]. Again, an
increase in the tGSH levels was observed in response to SNAP
treatment detectable at 8 h and reaching a maximum at 12 h
of exposure (Fig. 1B).
To determine the exposure of the cells to NO under these
conditions, the rate of oxidation of oxymyoglobin was deter-
mined as a function of the SNAP concentration. Similar to
other NO donors, release of NO from SNAP occurred in a
cell-dependent manner and was saturable (with an apparent
Km of approximately 15 WM for SNAP). The maximal rates of
NO release were 1 nM/s, with 50^100 WM SNAP, which
would be a rate of NO production readily achieved during
the physiological activation of eNOS [21,23].
The S-nitrosothiols have other biochemical mechanisms
through which they can exert their e¡ects including transfer
of the nitrosonium group to another thiol via a transnitrosa-
tion reaction [31]. To rule out this mechanism, the compound
DetaNONOate was used as an NO donor which has a di¡er-
ent mechanism of NO release, chemistry and decomposition
products than SNAP [28]. The results are shown in Fig. 2 in
comparison with SNAP and indicate that DetaNONOate was
also able to induce tGSH synthesis. The decomposition prod-
ucts of either SNAP or DetaNONOate had no signi¢cant
e¡ect on tGSH levels in the cells, nor was cytotoxicity de-
tected in the presence of NO donors at this concentration
(result not shown). The rate of NO release from 100 WM
DetaNONOate was calculated from its published half life
(20 h). Taking into account that two NO molecules are re-
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Fig. 1. The induction of total GSH in endothelial cells by NO. En-
dothelial cells were exposed to increasing concentrations of SNAP
(E) or its decomposition products (a) (A) for a period of 12 h be-
fore the measurement of tGSH. Cells were lysed with Triton X-100
(0.1%) in PBS and the tGSH content was determined and normal-
ized to protein. In B, the result of exposing cells to 500 WM SNAP
for the periods shown on tGSH was determined. Data are repre-
sented as the mean þ S.E.M., n = 3^4. *Signi¢cantly di¡erent to
control, (P6 0.01).
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leased for each molecule of the NONOate, the rate of NO
release was approximately 1^1.6 nM/s, similar to that found
with SNAP [28]. This rate of NO formation is approximately
250 times lower than the rates reported to be cytotoxic to cells
in culture and leading to an initial depletion of tGSH [32^34].
The NO-dependent increase in tGSH may occur through
a¡ecting the activity of enzymes, such as GSH peroxidase
(GPx), which use GSH as a substrate. Treatment of either
VSMCs or BAECs with SNAP for 4 h did not a¡ect the
activity of either GPx or catalase (data not shown) indicating
that the changes in the tGSH levels with NO treatment were
not due to changes in the activity of these enzymes. Although
an increase in tGSH clearly occurs in BAECs on exposure to
NO, this would not result in an increased antioxidant capacity
of the cell if the antioxidant is predominantly in its oxidized
form (GSSG). To test for this possibility, cells were exposed
to 200 WM SNAP for a period of 12 h before the measurement
of GSH and GSSG by HPLC. The tGSH increased by 2.5-
fold while the ratio of GSH:GSSG was 19.7 þ 0.7 for decom-
posed SNAP, 17.6 þ 1.2 for the control (untreated cells) and
increased to 57 þ 0.7 for cells exposed to SNAP (all data =
mean þ S.E.M, n = 3). These data indicate that GSH-depend-
ent antioxidant defenses have been enhanced by exposure to
NO.
3.2. Induction of GSH synthesis by NO is cGMP- and
guanylate cyclase-independent
To test the potential role of the NO soluble guanylate cy-
clase signalling pathway in the induction of tGSH synthesis,
two approaches were taken. Firstly, endothelial cells were in-
cubated with a cell permeable cGMP analog, 8-bromo cGMP
(500 WM), followed by measurement of tGSH content, 12 h
later (Fig. 2). The cGMP analog had no signi¢cant e¡ect on
tGSH levels at this concentration, which was selected to be
equivalent to the maximal activation of guanylate cyclase [35].
In the second approach, the inhibitor of guanylate cyclase,
1H-(1,2,4) oxadiazolo(4,3,-K) quinoxalin-1-one (ODQ), was
used in the presence or absence of SNAP. After exposure of
the cells to ODQ (3 WM), in the presence or absence of the
NO donor, tGSH was measured in the cells. This concentra-
tion of ODQ has been shown to inhibit guanylate cyclase in a
number of biological preparations [20]. As shown in Fig. 2,
ODQ did not prevent the increase in the tGSH induced by
SNAP. It is clear that the tGSH levels were not a¡ected by
either treatment, indicating that the cGMP pathway was not
involved in the NO-dependent induction of GSH synthesis.
3.3. NO induces GSH synthesis via an increased GCS
activity
The rate-limiting enzyme for GSH synthesis is GCS and it
is therefore a potential candidate for activation by the NO
donors. To test whether GCS activity is increased by NO,
the activity was measured in cell lysates after treatment with
SNAP (100 and 200 WM) for 12 h and is shown plotted
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Table 1
Acivicin blocks the NO-dependent increase in tGSH
Sample Cellular GSH (nmol/mg protein) Medium GSH (nmol/mg cell protein)
Control 36.8 þ 1.3 3.8 þ 0.2
100 WM DetaNONOate 61.1 þ 2.8 10.0 þ 1.2
100 WM DetaNONOate+5WM acivicin 37.4 þ 1.5 14.3 þ 2.3
5 WM Acivicin 37.6 þ 3.4 6.0 þ 0.8
BAECs were treated in vitro with either 100 WM detaNONOate, 5 WM acivicin or both, for 16 h. Media were collected and cells were rinsed twice
with ice-cold PBS plus 0.1% Triton and 10 WM DTPA and the concentration of GSH was measured. The tGSH measured in the media was
predominantly (more than 90%) in the form of GSH as determined by the direct measurement of reduced thiol with DTNB. The medium GSH is
normalized to the protein concentration in the cell lysate to correct for variability in the cell growth or seeding density.
Fig. 3. Increase in the GCS activity in endothelial cells. A: GCS ac-
tivity was measured as described in Section 2 and was 7.21 þ 0.3
nmol/mg/h (mean þ S.E.M., n = 6) for the control untreated samples.
It is shown plotted as a function of the fold increase in tGSH for
groups of cells treated with 100 or 200 WM SNAP (Figure 1, E).
The line shows the linear ¢t to the data and the correlation is sig-
ni¢cant (P6 0.03).
Fig. 2. The e¡ect of cGMP analogs and inhibition of guanylate cy-
clase on the induction of GSH in endothelial cells. Endothelial cells
were exposed to the cell permeable cGMP analog 8-bromo-cGMP
(500 WM), 200 WM SNAP in the presence and absence of 3 WM
ODQ, or 50 or 100 WM DetaNONOate. The vehicle for ODQ was
DMSO, present at a ¢nal concentration of 0.1%. The fold increases
in tGSH levels are shown following exposure to various treatments
for 12 h. The control values for tGSH in untreated cells were be-
tween 18 and 25 nmol tGSH/mg protein for the di¡erent experi-
ments. Data are represented as the mean þ S.E.M., n = 3^4, *signi¢-
cantly di¡erent to control (P6 0.01).
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against the fold increase in tGSH (Fig. 3). A small change in
the GCS activity of 1^1.3-fold was associated with increases
of 2^3-fold in the tGSH. These data are consistent with a
number of reports using di¡erent stimuli and indicate that
an increase in the activity of the enzyme of this magnitude
can result in the 2^4-fold increase in tGSH that is observed
[24^26]. However, this result does not rule out a contribution
from other elements in the GSH biosynthetic pathway, includ-
ing activation of the plasma membrane enzyme Q-GT or the
cystine transporter [36^39]. To test for an e¡ect of Q-GT, cells
were treated with the inhibitor of the enzyme, acivicin, in the
absence or presence of DetaNONOate and the results are
reported in Table 1. Treatment with NO alone increased
tGSH in both the cells and that exported to the medium.
Treatment with acivicin alone had no signi¢cant e¡ect on
tGSH and caused a modest increase in the tGSH present in
the medium. In combination with the NO donor, acivicin
prevented the increase in the cell tGSH and increased further
the concentration of tGSH in the medium. The GSH (5 þ 1.25
WM, mean þ S.E.M., n = 3) in the medium without cells was
over 90% in the reduced form and presumably derived from
the fetal calf serum. The media also contains 200 WM cystine
that can be transported into cells, reduced and then serves as
a further source of substrate for the GSH synthesis. These
data are consistent with a requirement for the metabolism
of GSH by Q-GT, although the activity of the enzyme will
be needed to con¢rm this result, for the NO-dependent syn-
thesis of GSH in the cell.
3.4. Summary
Both NO and GSH are thought to play an important role
in the protection of the cells in the vasculature from oxidative
stress. For example, the ability of macrophages and endothe-
lial cells to resist the cytotoxicity of oxLDL is critically de-
pendent on intracellular GSH levels [40,41]. While NO or its
metabolites can react with other oxidants to promote nitration
or oxidation reactions, NO per se appears to protect cells
against oxidants including oxLDL [1^3]. The reactions of
NO are then dependent on both its concentration and on
the presence of other molecular species with which it can
react. Herein, we extend recent observations with VSMCs to
show that an indirect mechanism for the antioxidant action of
NO is the regulation of the intracellular antioxidant GSH [20].
In contrast to the results with smooth muscle cells, the induc-
tion of GSH synthesis in endothelial cells occurred in response
to a substantially lower rate of NO formation. These rates of
NO formation (1^3 nM/s) are within the range required for
endothelial (type III) NOS to elicit vasorelaxation [23]. Our
data indicate that this NO signalling pathway functions inde-
pendently of the activation of soluble guanylate cyclase.
The requirement shown here for Q-GT activity in the NO-
dependent increase in GSH is similar to that found in re-
sponse to redox cycling xenobiotics. For example, the Q-GT-
speci¢c activity and transcription is elevated by quinones that
redox cycle or deplete GSH through conjugation such as 2,3-
dimethoxy-1,4-naphthoquinone [42]. Pretreatment with acivi-
cin, an inhibitor of Q-GT, also prevented the TBHQ-induced
increase in GSH and markedly diminished the resistance to
the cytotoxicity of 200 WM TBHQ. We have not determined
whether the Q-GT activity is increased in response to NO but
this is a likely outcome since the GSH metabolic cycle, includ-
ing the cystine transporter, appears to be coordinately regu-
lated [18].
The mediators involved in the NO-dependent signalling for
GCS are not clear. If the production of secondary oxidants,
such as peroxynitrite, are involved, they likely serve a signal-
ling function since the NO exposures are two orders of mag-
nitude lower than those concentrations that are cytotoxic. It is
postulated, therefore, that a potentially cooperative interac-
tion between NO and GSH may be important in enhancing
the antioxidant properties of endothelium and to protect
against the cytotoxic e¡ects of nitrosative or oxidative stress.
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